Nephrogenic gadolinium biodistribution and skin cellularity following a single injection of omniscan in the rat

Investigative Radiology

Volumn 45, Issue 9, 2010, Pages 507-512

  Haylor, John ^a   Dencausse, Anne ^b   Vickers, Melissa ^a   Nutter, Faith ^a   Jestin, Gaelle ^b   Slater, David ^c   Idee, Jean Marc ^b   Morcos, Sameh ^d  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Laboratoire Guerbet   (France)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

gadodiamide; gadolinium; glomerular filtration rate; nephrogenic systemic fibrosis

Indexed keywords

CD34 ANTIBODY; CREATININE; GADODIAMIDE; GADOLINIUM; ISOFLURANE; SODIUM CHLORIDE;

ANESTHESIA INDUCTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CONCENTRATION (PARAMETERS); CONTRAST; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG DISTRIBUTION; DRUG RETENTION; GLOMERULUS FILTRATION RATE; KIDNEY FUNCTION; KIDNEY SURGERY; MALE; MASS SPECTROMETRY; NEPHRECTOMY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PLASMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; SHAM PROCEDURE; SINGLE DRUG DOSE; SKIN CELL; SKIN DEFECT; WISTAR RAT;

EID: 77955452274     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181eb51f2     Document Type: Article

References (21)

1. Idee JM, Port M, Raynal I, et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol. 2006;20:563-576.
2. Cowper SE. Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium. Adv Dermatol. 2007;23:131-154.
3. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol. 2007;80:73-76.
4. Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadoliniumbased contrast media. Invest Radiol. 2008;43:65-75.
5. Grant D, Johnsen H, Juelsrud A, et al. Effects of gadolinium contrast agents in naive and nephrectomized rats: relevance to nephrogenic systemic fibrosis. Acta Radiol. 2009;50:156-169.
6. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1-S266.
7. Spencer K. Analytical reviews in clinical biochemistry: the estimation of creatinine. Ann Clin Biochem. 1986;23:1-25.
8. Frame EM, Uzgiris EE. Gadolinium determination in tissue samples by inductively coupled plasma mass spectrometry and inductively coupled plasma atomic emission spectrometry in evaluation of the action of magnetic resonance imaging contrast agents. Analyst. 1998;123:675-679.
9. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Am J Roentgenol. 2007;188:586-592.
10. Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol. 2009;4:461-469.
11. US Food and Drugs Administration CDER. Guidance for industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. J:\!GUIDANC5541fnlcln. 1.doc. 2005:1-27. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ ucm078932.pdf.
12. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol. 1995;30:372-380.
13. Abraham JL, Thakral C. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. Eur J Radiol. 2008;66:200-207.
14. Pietsch H, Lengsfeld P, Steger-Hartmann T, et al. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol. 2009;44: 226-233.
15. Harpur ES, Worah D, Hals PA, et al. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol. 1993;28(suppl 1):S28-S43.
16. Abraham JL, Thakral C, Skov L, et al. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol. 2008;158:273-280.
17. Spasovski GB, Sikole A, Gelev S, et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant. 2006;21:2217-2224.
18. Pietsch H, Lengsfeld P, Jost G, et al. Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents. Eur Radiol. 2009;19:1417-1424.
19. Pietsch H, Pering C, Lengsfeld P, et al. Evaluating the role of zinc in the occurrence of fibrosis of the skin: a preclinical study. J Magn Reson Imaging. 2009;30:374-383.
20. Haylor J, Chowdry J, Baillie H, et al. Renal function and morphometry in the dwarf rat following a reduction in renal mass. Nephrol Dial Transplant. 1996;11:643-650.
21. Brasch RC, Chaopathomkul B, Rogut VS, et al. Modelling nephrogenic systemic fibrosis in renal failure rats testing three gadolinium-based contrast media in clinically relevant dosages. Eur Radiol. 2009;19(suppl 1):S285.